Recent developments include corporate governance changes, clinical data announcements, market actions, and financial reporting updates.

• Orgenesis expanded its board with three new appointments in November 2024 [N3].
• The company reported Q3 EPS of ($1.93) compared to ($0.12) in the prior year, reflecting ongoing losses [N2].
• Orgenesis announced real-world clinical data for its ORG-101 CAR-T therapy for CD19+ acute lymphoblastic leukemia, highlighting strong safety and efficacy [N6].
• The company unveiled an investor presentation with forward-looking insights in May 2024 [N7].
• Orgenesis approved a 1-for-10 reverse stock split in September 2024 [N5].
• The company commenced trading on the OTCQX Best Market in October 2024 but was later moved to lower OTC tiers due to SEC filing delays [N4].
• Recent insider trading and hedge fund activity were noted in an earnings preview in April 2025 [N1].

Orgenesis has developed a unique decentralized production platform that significantly reduces the cost and complexity of manufacturing cell and gene therapies, potentially enabling broader patient access. The company’s CAR-T therapy for CD19+ acute lymphoblastic leukemia has demonstrated strong real-world clinical efficacy and safety, supported by cost reductions of up to 73% compared to traditional methods. Expansion of the POCare Network and recent board appointments indicate efforts to strengthen governance and operational capacity. The company’s diverse pipeline and strategic partnerships position it to leverage emerging opportunities in the growing CGT market.

Orgenesis faces substantial financial challenges, including a net loss of $48.2 million in 2024, extremely low liquidity with a current ratio of 0.03, and expressed substantial doubt about its ability to continue as a going concern without immediate additional capital. The company’s stock has been delisted from Nasdaq and downgraded to lower OTC tiers due to SEC filing delays, limiting market visibility and liquidity. Dependence on external financing, potential dilution from equity issuances, and ongoing operational risks including regulatory and manufacturing challenges pose significant hurdles. The novel nature of its therapies and decentralized production model also entail regulatory uncertainties and execution risks.

Orgenesis’ moat is centered on its proprietary decentralized cell processing (DCP) platform, which offers a scalable, automated, and standardized approach to producing advanced cell and gene therapies near patient care sites. This platform addresses key industry challenges such as high production costs, complex logistics, and scalability limitations inherent in traditional centralized manufacturing. The company’s integration of quality control, regulatory compliance, and data management within the DCP network supports replicability and efficiency. Additionally, Orgenesis’ partnerships with hospitals, research centers, and industry players, along with its diverse portfolio of production platforms and therapies, contribute to its competitive positioning. However, the company’s financial instability and ongoing need for capital may constrain its ability to fully capitalize on these advantages.

• Liquidity and Going Concern Risk: Orgenesis has very limited cash and current assets relative to its current liabilities, with a current ratio of 0.03 as of December 31, 2024. The company and its auditors have expressed substantial doubt about its ability to continue as a going concern without immediate additional capital.
• Regulatory and Manufacturing Challenges: The company’s therapies and decentralized production platforms face complex regulatory approval processes with limited precedents. Manufacturing scale-up and quality control in decentralized units present operational risks.
• Market and Trading Risks: Delisting from Nasdaq and trading on lower OTC tiers reduce liquidity, market visibility, and may impair the company’s ability to raise capital or attract institutional investors.
• Dependence on External Financing: Orgenesis relies on financing from specific funds and requires shareholder approval for capital raises. Failure to secure financing on acceptable terms could lead to restructuring or liquidation.
• Operational and Execution Risks: The company’s business model depends on partnerships, technology development, and commercialization of novel therapies, which involve inherent risks of failure, delays, or inability to generate significant revenues.

• Orgenesis Inc. is a global biotech company focused on cell and gene therapies (CGTs), particularly using a decentralized cell processing (DCP) platform to produce advanced therapy medicinal products (ATMPs) near patient care sites to reduce costs and improve access [S1].
• The DCP platform includes standardized, automated, and closed production units with integrated quality control and regulatory compliance, aiming to overcome limitations of traditional centralized manufacturing [S1].
• Orgenesis develops and commercializes multiple production platforms for various cell types, including pancreatic islets (Koligo platform), CAR-T therapies (CAR-T8-TOR platform), stromal vascular fraction (Icellator2 platform), MSC oncolytic virus (TROJAN platform), tumor-infiltrating lymphocytes (LYMVADOR platform), hematopoietic stem cells (HEMOSTART platform), dendritic vaccines (IdenTT platform), induced pluripotent stem cells (Mida platform), and exosomes production [S1].
• The company operates a POCare Network partnering with hospitals, research centers, and industry partners globally to provide decentralized production and cell processing services [S1].
• Orgenesis generates revenue from out-licensing therapies, POCare development services, cell process development, and hospital services, with total revenue of approximately $1.035 million in 2024, up from $0.53 million in 2023 [S1].
• The company has multiple subsidiaries focused on R&D, production, and management services across the US, Europe, Israel, and other regions; some subsidiaries have entered liquidation [S1].
• Orgenesis reported a net loss of approximately $48.2 million for the fiscal year ended December 31, 2024, with cash and cash equivalents of $78,000 and current liabilities of $26.92 million, resulting in a very low current ratio of 0.03 as of 2024-12-31 [S1].
• The company implemented a 1-for-10 reverse stock split on September 20, 2024, and commenced trading on the OTCQX Best Market on October 21, 2024, but was subsequently moved to lower OTC tiers due to delays in SEC filings [S1].
• Orgenesis faces substantial doubt about its ability to continue as a going concern due to insufficient funds to service operations and liquidity needs, requiring immediate additional capital [S1].
• The company is reliant on financing from Alpha Prosperity Fund SPC and requires shareholder approval for further capital raises; failure to secure financing could lead to restructuring or liquidation [S1].
• Orgenesis has a diverse pipeline of cell and gene therapies in various stages, including advanced anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia with reported real-world clinical data showing high efficacy and safety [S1][N6].
• The CAR-T therapy production cost is reduced by 73% using the DCP platform compared to traditional centralized manufacturing, enhancing cost-effectiveness [S1].
• The company has expanded its board with three new appointments as of November 2024 [N3].
• Orgenesis reported Q3 EPS of ($1.93) compared to ($0.12) last year, indicating continued losses [N2].
• The company announced real-world data of its ORG-101 CAR-T therapy for CD19+ acute lymphoblastic leukemia, highlighting strong safety and efficacy [N6].
• Orgenesis unveiled an investor presentation with forward-looking insights in May 2024 [N7].
• The company approved the 1-for-10 reverse stock split in September 2024 [N5].
• Orgenesis commenced trading on the OTCQX Best Market in October 2024 [N4].
• Recent insider trading and hedge fund activity were noted in an earnings preview in April 2025 [N1].